![Tim Osborne](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Patrimonio netto: 321 957 $ in data 30/06/2026
Tim Osborne worked as Principal at the University of California, Irvine.
Mr. Osborne worked as Advisor at Select BioVentures LLC.
Mr. Osborne worked as Senior Vice President-Operations at Forward Air Corp.
from 2013 to 2024.
Mr. Osborne completed undergraduate education at King University.
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
| 15/03/2026 | 23.831 ( 0,08% ) | 321 957 $ | 30/06/2026 |
| Società | Posizione | Fine |
|---|---|---|
University of California, Irvine
 University of California, Irvine Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | - |
| FORWARD AIR CORPORATION | Direttore operativo | - |
Select BioVentures LLC
 Select BioVentures LLC Investment ManagersFinance Select BioVentures focuses on investments in Florida-based and other bioscience companies. The firm seeks to invest in late pre-clinical and early clinical stage private or public biopharmaceutical, medical device and molecular diagnostic companies. | Investitore di Private Equity | - |
Attive
Inattive
Società nel listino
Aziende private
| Aziende private | 4 |
|---|---|
Forward Air Corp.
 Forward Air Corp. TruckingTransportation Provides less-than-truckload, final mile, truckload and intermodal drayage services | Transportation |
King University
 King University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of California, Irvine
University of California, Irvine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Select BioVentures LLC
Select BioVentures LLC Investment ManagersFinance Select BioVentures focuses on investments in Florida-based and other bioscience companies. The firm seeks to invest in late pre-clinical and early clinical stage private or public biopharmaceutical, medical device and molecular diagnostic companies. | Finance |
Seleziona la tua edizione
Tutte le informazioni finanziarie adattate in base al livello nazionale
